Should Certain Antihyperglycemic Medications Be Preferred Over Antihypertensive Medications for Blood Pressure Control in Special Populations With Diabetes Mellitus?

Affiliations

Editorial

Kenneth A Jamerson. Circulation. 2019.

. 2019 Apr 30;139(18):2110-2112.

doi: 10.1161/CIRCULATIONAHA.119.039044.

No abstract available

Keywords: Editorials; blood pressure; cardiovascular diseases; diabetes mellitus; empagliflozin; sodium-glucose cotransporter 2 inhibitors.

Comment on

Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, Uchiyama K, Niijima Y, Katsuya T, Urata H, Osuga JI, Fujiwara T, Yamazaki S, Tomitani N, Kanegae H. Kario K, et al. Circulation. 2019 Apr 30;139(18):2089-2097. doi: 10.1161/CIRCULATIONAHA.118.037076. Epub 2018 Nov 29. Circulation. 2019. PMID: 30586745 Free PMC article.
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, Seman L. Ferdinand KC, et al. Circulation. 2019 Apr 30;139(18):2098-2109. doi: 10.1161/CIRCULATIONAHA.118.036568. Circulation. 2019. PMID: 30786754 Clinical Trial.